GGrantIndex
Sort

8,912 grants matching sars cov 2

Center for Excellence in Host Pathogen Interactions

$2,073,225
David S. Bradley · University Of North Dakota · P20 · FY2022 · GM

Immune Responses to Malaria, HIV and SARS-CoV-2 Infection and Immunization

$2,071,529
Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2022 · AI

Cardiovascular Genomics and Bioinformatics projects

$2,064,651
Andrew Johnson · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL

Molecular Approaches To Antiviral Development For Viral Hepatitis and Other Viral Diseases

$2,063,799
T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK

Center for Excellence in Host Pathogen Interactions

$2,063,090
David S. Bradley · University Of North Dakota · P20 · FY2021 · GM

Integrative Immunogen Design and Testing

$2,060,891
Erica Ollmann Saphire · Brigham And Women'S Hospital · P01 · FY2023 · AI

ALZHEIMERS RESEARCH PROJECT: Developing Extraceullar Vesicle biomarkers for clinical and preclinical AD/ADRD

$2,057,404
Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2024 · AG

Early detection and inference for emerging infectious agents in data-sparse settings

$2,056,250
Sen Pei · Columbia University Health Sciences · R35 · FY2025 · GM

Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses

$2,044,217
Fred R Hirsch · Icahn School Of Medicine At Mount Sinai · U54 · FY2022 · CA

Emerging respiratory viruses - pathogenesis and countermeasures

$2,042,870
Emmie De Wit · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

A Follow-up Study for Causes of Cancer in Black Women

$2,042,803
Julie R Palmer · Boston University Medical Campus · U01 · FY2023 · CA

Center for Excellence in Host Pathogen Interactions

$2,038,822
David S. Bradley · University Of North Dakota · P20 · FY2023 · GM

A Follow-up Study for Causes of Cancer in Black Women

$2,035,759
Julie R Palmer · Boston University Medical Campus · U01 · FY2024 · CA

The COVID-19 pandemic: Impact on mental health and HIV outcomes

$2,035,602
Keri Nicole Althoff · Johns Hopkins University · RF1 · FY2023 · MH

Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses

$2,034,822
Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

CoVPN 3006: A randomized controlled study to assess SARS-CoV-2 infection, viral shedding, and subsequent potential transmission in university students immunized with Moderna COVID-19 Vaccine

$2,034,708
Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2021 · AI

Applying Bioinformatics to Research in Immune, Muscle, and Bone Diseases

$2,033,275
Hong-Wei Sun · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIC · FY2025 · AR

Mechanism and Regulation of Eukaryotic Protein Synthesis

$2,032,638
Thomas E Dever · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2022 · HD

Role of O-glycosylation in Animal Development

$2,025,039
Kelly G Ten Hagen · National Institute Of Dental & Craniofacial Research · ZIA · FY2021 · DE

Kaiser Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012

$2,014,564
Lisa A Jackson · Kaiser Foundation Research Institute · UM1 · FY2021 · AI

Mechanism and Regulation of Eukaryotic Protein Synthesis

$2,009,782
Thomas E Dever · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2023 · HD

Clinical and Informatics Research on Large Clinical Databases

$2,008,861
Clement McDonald · National Library Of Medicine · ZIA · FY2023 · LM

Significant expansion of the SNPRC ABSL3 capability in the wake of COVID-19

$2,000,000
Larry S. Schlesinger · Texas Biomedical Research Institute · P51 · FY2020 · OD

Wastewater Detection of COVID-19

$2,000,000
Jeff Wenzel · Missouri State Dept/ Health & Senior Srv · U01 · FY2021 · DA

Prospective Cohort to Assess Novel and Repeated SARS-CoV-2 Infection and COVID-19 Illness within a US State or Region

$2,000,000
National Cancer Institute · Y01 · FY2021 · CA